Teriparatide (PTH 1-34) is also an osteoporosis medication which can increase bone formation via PKA (protein kinase A) and Wnt/β-catenin pathways (Tian et al., 2011), and also increases the secretion of OPG. The gene discussed is TNFRSF11B; the disease is osteoporosis.